UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 89

Sortiert nach

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

The lancet oncology, 2015-01, Vol.16 (1), p.76-86

2015

Link zum Volltext

Verfügbarkeit prüfen

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients

Frontiers in oncology, 2023-09, Vol.13, p.1265812-1265812

2023

Link zum Volltext

Verfügbarkeit prüfen

Extensive surgical resections for rare pleural neoplasms: a single-center experience with a yolk sac tumor and synovial sarcoma

World journal of surgical oncology, 2024-04, Vol.22 (1), p.96-96

2024

Link zum Volltext

Verfügbarkeit prüfen

Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy

World journal of urology, 2019-09, Vol.37 (9), p.1857-1866

2019

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

Gastroenterology (New York, N.Y. 1943), 2005-02, Vol.128 (2), p.270-279

2005

Link zum Volltext

Verfügbarkeit prüfen

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial

BMC cancer, 2020-05, Vol.20 (1), p.457-7, Article 457

2020

Link zum Volltext

Verfügbarkeit prüfen

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

Investigational new drugs, 2008-10, Vol.26 (5), p.483-488

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

Investigational new drugs, 2015-06, Vol.33 (3), p.611-620

2015

Link zum Volltext

Verfügbarkeit prüfen

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group

European journal of cancer (1990), 2002-09, Vol.38, p.S83-S87

2002

Link zum Volltext

Verfügbarkeit prüfen

Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma

Expert opinion on pharmacotherapy, 2008-06, Vol.9 (9), p.1609-1618

2008

Link zum Volltext

Verfügbarkeit prüfen

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma

Sarcoma, 2017, Vol.2017, p.1781087-7

2017

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

The lancet oncology, 2020-12, Vol.21 (12), p.1574-1588

2020

Link zum Volltext

Verfügbarkeit prüfen

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

The New England journal of medicine, 2019-12, Vol.381 (26), p.2506-2518

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma

Marine drugs, 2009-03, Vol.7 (1), p.57-70

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium

Marine drugs, 2009-09, Vol.7 (3), p.451-463

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors

Clinical cancer research, 2003-11, Vol.9 (14), p.5195-5204

2003

Link zum Volltext

Verfügbarkeit prüfen

Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography–tandem mass spectrometry

Journal of Chromatography A, 2003-12, Vol.1020 (1), p.27-34

2003

Link zum Volltext

Verfügbarkeit prüfen

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

European journal of cancer (1990), 2012-01, Vol.48 (2), p.179-186

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2005-10, Vol.11 (19), p.6908-6915

2005

Link zum Volltext

Verfügbarkeit prüfen

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

The Lancet (British edition), 2017-11, Vol.390 (10109), p.2266-2277

2017

Link zum Volltext

Verfügbarkeit prüfen

Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study

Acta oncologica, 2022-01, Vol.61 (1), p.22-29

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours

Journal of controlled release, 2020-09, Vol.325, p.191-197

2020

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study

Anti-cancer drugs, 2007-02, Vol.18 (2), p.211-218

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(85)

Publikationsform

Artikel
(88)
Buchkapitel
(1)

Sprache

Englisch
(89)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

Extensive surgical resections for rare pleural neoplasms: a single-center experience with a yolk sac tumor and synovial sarcoma

Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial

SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group

Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma

Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium

Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors

Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography–tandem mass spectrometry

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study

A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours

Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study

Suchergebnisse filtern